Aura Biosciences (AURA) Net Cash Flow (2020 - 2026)
Aura Biosciences' (AURA) quarterly Net Cash Flow came in at $25.3 million in Q1 2026, up 286.1% YoY from $6.6 million in Q1 2025, and up 108.03% on a QoQ basis from $12.2 million in Q4 2025.
Aura Biosciences (AURA) Net Cash Flow (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Net Cash Flow data on file, last reported at $25.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 286.1% year-over-year to $25.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.8 million (up 291.05% YoY) and the FY2025 annual result came in at $28.0 million, up 398.75% from the prior year.
- Net Cash Flow advanced to $25.3 million in Q1 2026, from $12.2 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $69.1 million in Q2 2025 to a low of -$83.1 million in Q1 2023.
- A 5-year average of -$3.7 million and a median of $6.3 million in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 1721.18% in 2025, down 1181.06% in 2025.
- Tracing AURA's Net Cash Flow over 5 years: stood at $60.3 million in 2022, then sank by 124.08% to -$14.5 million in 2023, then soared by 143.29% to $6.3 million in 2024, then soared by 93.51% to $12.2 million in 2025, then jumped by 108.03% to $25.3 million in 2026.
- The last three Net Cash Flow figures came in at $25.3 million (Q1 2026), $12.2 million (Q4 2025), and -$59.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | -16.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.78 Mn |
| Jun 30, 2026 | -16.78 Mn |
| Mar 31, 2026 | 25.31 Mn |
| Mar 31, 2026 | 25.31 Mn |
| Dec 31, 2025 | 12.16 Mn |
| Dec 31, 2025 | 12.16 Mn |
| Sep 30, 2025 | -59.80 Mn |
| Sep 30, 2025 | -59.80 Mn |
| Jun 30, 2025 | 69.13 Mn |
| Jun 30, 2025 | 69.13 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Dec 31, 2024 | 6.29 Mn |
| Dec 31, 2024 | 6.29 Mn |
| Sep 30, 2024 | -4.67 Mn |
| Sep 30, 2024 | -4.67 Mn |
| Jun 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 3.80 Mn |
| Mar 31, 2024 | -14.80 Mn |
| Mar 31, 2024 | -14.80 Mn |